ScoreWhy is Oncopeptides AB ?
1
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 251.62%, its profits have fallen by -1.7%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Oncopeptides AB for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Oncopeptides AB
251.62%
0.50
110.85%
OMX Stockholm 30
8.01%
0.44
18.11%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
129.44%
EBIT Growth (5y)
12.53%
EBIT to Interest (avg)
-546.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.91
Sales to Capital Employed (avg)
0.29
Tax Ratio
0.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-19.96
EV to EBIT
-5.24
EV to EBITDA
-5.24
EV to Capital Employed
-108.59
EV to Sales
27.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
NET PROFIT(HY)
Higher at SEK -144.09 MM
ROCE(HY)
Highest at 0%
NET SALES(Q)
Highest at SEK 13.27 MM
RAW MATERIAL COST(Y)
Fallen by -6.75% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -191.03 %
DEBTORS TURNOVER RATIO(HY)
Highest at 0.88%
OPERATING PROFIT(Q)
Highest at SEK -60.67 MM
OPERATING PROFIT MARGIN(Q)
Highest at -457.34 %
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Oncopeptides AB
Net Sales
Highest at SEK 13.27 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (SEK MM)
Net Sales
At SEK 13.27 MM has Grown at 67.68%
over average net sales of the previous four periods of SEK 7.91 MMMOJO Watch
Near term sales trend is very positive
Net Sales (SEK MM)
Net Profit
Higher at SEK -144.09 MM
than preceding 12 month period ended Mar 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (SEK MM)
Operating Profit
Highest at SEK -60.67 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (SEK MM)
Operating Profit Margin
Highest at -457.34 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Debt-Equity Ratio
Lowest at -191.03 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 0.88%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -6.75% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
